Ubiquitination is a crucial post-translational modification process where the small protein ubiquitin is attached to target proteins, marking them for degradation or altering their function. This ...

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, ...

Pancreatic cancer is a rare disease; however, its initially inconspicuous symptoms and aggressive nature make it one of the deadliest forms of cancer.

For tissues to cooperate and perform normal functions, cells need to know which way is up. When cells lose track of their orientation, they can start to grow out of control, and develop into cancer.

Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.

Human papillomavirus (HPV) can drive tumor development in some rare sinonasal squamous cell carcinomas (SNSCCs), according to a new comprehensive study of these tumors from investigators at the Johns ...

Gliomas are cancers that originate directly in the brain, instead of spreading to the brain from other parts of the body. These cancers cannot be cured with conventional cancer treatments, as they ...

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal DNA methylation measurements and comprehensive ...

When you think about brain tumors, you might assume they’re purely a matter of bad genetic luck or something that happens to “other people.” But emerging research suggests that various factors in our ...